"Ben Lipps, the CEO of Fresenius Medical Care, came by to speak with us this week. The German company runs dialysis centers around the world, so we were eager to ask Lipps about the ongoing controversy over the use of anemia drugs (such as Amgen’s Epogen) at U.S. dialysis centers."
The original post is at the Wall Street Journal Health Blog.